BioSpace News Archive

Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a global study in the Journal of Electrophoresis: Global Intercompany Assessment of icIEF Platform Comparability for the Characterization of Therapeutic Proteins.

Codagenix Inc. today announced the first patient has been dosed in a U.K.-based Phase 1 clinical trial to evaluate the use of Codagenix’s novel intranasal, live-attenuated virus vaccine, CoviLiv™, as a booster in healthy adults following prior vaccination with approved COVID-19 vaccines.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, president and chief executive officer, will present at the Jefferies Healthcare Conference, being held in New York, NY and virtually, on Wednesday, June 8, 2022 at 3:00 p.m. ET.

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022.

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will be participating at three upcoming investor conferences.

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to seribantumab.

Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week ® (DDW) 2022.

QurAlis Corporation today announced that Kasper Roet, Ph.D., founder and chief executive officer (CEO) and Angela Genge, M.D., chief medical officer (CMO), will deliver presentations at the ALS Drug Development Summit being held May 24-26, 2022 in Boston, Massachusetts.

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of Health (NIH) Intramural Research Program-sponsored study titled “An Observational Study of Neurologic Function after COVID-19 Infection” utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology.